PT-141 underdosing: a pattern across three companies
Every PT-141 product we have tested since 2025 measured under label. The shortfalls cluster suspiciously.
InvestigationPT-141
Also known as: Bremelanotide, Vyleesi
ClassMelanocortin receptor agonist
Research statusFDA-approved (branded form)
Independent tests1
Studies indexed1
Overview
PT-141 (bremelanotide) is one of the few compounds in our index with full FDA approval in its branded form, following phase 3 trials for hypoactive sexual desire disorder. Gray-market versions of the compound remain widespread and are a regular subject of our quantity-verification testing.
Research & Studies
Studies library-
Bremelanotide for hypoactive sexual desire disorder (RECONNECT)
Paired phase 3 trials supporting FDA approval of bremelanotide (Vyleesi).
Independent Testing
Testing databaseLaboratory verification of PT-141 products across the companies we index.
PT-141 Helix Research Supply
Purity 97.6% Discrepancy
Latest Coverage
Community Discussions
Forum 19 replies
The Peptide Institute Weekly
Research. Testing. Regulation. No hype.
One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.
- New research, summarized in plain English
- Independent lab results as they publish
- Score and ranking movements